Article summary
In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic plasticity of psychedelics without the hallucinogenic side effects that complicate scalability, reimbursement, and patient access. At the center of this movement are Enveric Biosciences and Equulus Therapeutics, two companies with very different paths, but a shared destination: mainstream adoption. The post After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma? appeared first on Microdose.
Continue to the original publication for the complete article.